|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on November 21, 2002; DOI 10.1182/blood-2002-06-1691.
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Laboratory Medicine, Division of
Clinical Chemistry, Lund University, University Hospital, Malmö,
Sweden.
Protein C is a member of the vitamin K- dependent protein
family. Proteins in this family have similar Negatively charged phospholipid membranes play an
important role in blood coagulation, providing a suitable surface for
the assembly of enzyme-cofactor complexes, which efficiently convert circulating zymogens to active enzymes. Phosphatidylserine (PS) is a
key component in the negatively charged membrane that supports the
clotting reactions.1-3 In most cells, PS is normally
mainly present in the inner leaflet of the cell membrane, but certain cellular processes such as platelet activation result in the exposure of PS on the cell surface. The vitamin K-dependent coagulation proteins in plasma bind to the surface of negatively charged
phospholipid with a common mechanism involving the The nonvitamin K-dependent cofactors of blood coagulation also
interact with the phospholipid membranes, certain proteins being
membrane spanning, whereas others, such as factor V (FV) and factor
VIII (FVIII), contain binding sites for negatively charged phospholipid
membranes.2,10 FV circulates as a procofactor to activated
FV (FVa), which functions as a cofactor to activated FX (FXa) in the
activation of prothrombin to thrombin. Activated FVIII (FVIIIa) serves
a similar function in the FIXa-mediated activation of
FX.2,3
The protein C anticoagulant system, which includes the vitamin
K-dependent proteins protein C and protein S, regulates the activities
of FVa and FVIIIa by limited proteolysis (reviewed by Dahlbäck et
al11 and Esmon et al12). Protein C is
activated on the endothelial cell surface by the
thrombin-thrombomodulin complex, and the serine protease activated
protein C (APC) down-regulates coagulation by cleaving a limited number
of peptide bonds in each of FVa and FVIIIa. Protein S serves as
a cofactor to APC by increasing the affinity of APC for the
membrane13 and also by changing the distance of the active
site of APC relative to the membrane.14,15 In FVa
degradation, APC-mediated cleavages at Arg506 and Arg306 result in
inhibition of FVa activity, the Arg506 cleavage resulting in partial
inhibition of FVa activity,16,17 whereas the Arg306 cleavage completely inactivates FVa.16-18 Protein S is an
important cofactor for the Arg306 cleavage, whereas the Arg506 is less
affected by protein S.19 In the degradation of FVIIIa, the
effect of APC is stimulated by a synergistic APC cofactor activity
between protein S and the intact form of FV.20
A common mutation in FV, which replaces Arg506 with a Gln (FV
Leiden),21 results in a hypercoagulable condition known as APC resistance.22,23 This is the most common inherited
risk factor for venous thrombosis. Heterozygous deficiencies of protein C or protein S are other genetic risk factors for venous
thrombosis.23 The association between defects of the
protein C system and increased risk of thrombosis demonstrates the
biologic importance of the protein C system. Protein C is a candidate
for treatment of certain thrombotic states.24,25 Moreover,
APC has recently been shown to be efficient in the treatment of sepsis,
a life-threatening condition associated with hypercoagulation and
generalized inflammatory reactions.26 APC not only has
anticoagulant properties but also anti-inflammatory effects, which are
poorly understood.24 Whether the positive therapeutic
effects depend on both the anticoagulant and anti-inflammatory
properties of APC is not known.
Protein C interacts with negatively charged phospholipid membranes with
relatively low affinity.6 We have previously reported that
site-directed mutagenesis of positions 10 to 12, 32, and 33 in protein
C result in protein C variants with enhanced membrane-binding ability
and anticoagulant activity.7,8 We now report on novel Gla
domain mutations resulting in the creation of APC variants with very
high anticoagulant activity. The results provide insights into the link
between sequence variations of the Gla domain and the membrane-binding
properties and the importance of membrane binding for expression of APC
anticoagulant activity.
Materials
Phospholipid vesicles used in the FVa-degradation assay and for the
light-scattering measurements were prepared by sonication. The
phospholipids (10:90, or 20:80 wt/wt, PS/PC) were dissolved in
CHCl3/CHOH (9:1, vol/vol) in glass tubes and dried
under a mild flow of nitrogen. The phospholipids were resuspended in 2 mL 25 mM HEPES
(N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), 150 mM NaCl, pH 7.7 (HN buffer), and vigorously vortexed for 1 minute. The phospholipid suspension was then sonicated for 10 minutes at 37°C using XL-2020 SONICATOR, an ultrasonic liquid processor from MISONIX (NY). The phospholipid vesicles used for light-scattering experiments (20:80, wt/wt, PS/PC) were isolated by gel
filtration chromatography on Sepharose 4B, as described.32 The phospholipid concentration was determined with the Phospholipid B
kit (Wako Chemicals).
Recombinant proteins
Mutagenesis.
Mutagenesis was performed using polymerase chain reaction
(PCR), essentially as previously described.8 To construct
the protein C variant D23S/Q32E/N33D/H44Y (SEDY), the cDNA for the protein C variant Q32E/N33D (ED)8 was first used as
template to introduce the D23S (Asp23Ser) mutation. The codon
for amino acid at position 23 was changed to AGC using PCR, the sense
and antisense mutant PCR primers containing 15 matching nucleotides on
each side of the mutant codon. The resulting cDNA for the SED variant
was further mutated at position 44, replacing the codon for His with a
codon for Tyr (TAC) by PCR-based mutagenesis, as described above. The
360-base pair (bp) cDNA fragment containing the SEDY mutations was
isolated after HindIII-SalI digestion and ligated
together with the SalI-XbaI fragment representing
the remaining part of the protein C cDNA into
HindIII-XbaI-cleaved pRc/CMV vector. The
H10Q/S11G/S12N (QGN) protein C variant was created with similar
methodology using mutant PCR primers introducing codons for Gln (CAA),
Gly (GGC), and Asn (AAC) at positions 10 to 12. After the PCR,
the cDNA was digested with BsrBI and the 200 bp 5'
fragment isolated and ligated with the BsrBI-XbaI fragment representing the remaining protein cDNA into
HindIII-XbaI-digested pRc/CMV vector. To
construct the H10Q/S11G/S12N/D23S/Q32E/N33D/H44Y (QGNSEDY) variant, the
HindIII-BsrBI fragment from QGN was ligated with
the BsrBI-XbaI fragment from SEDY into the
HindIII-XbaI-digested pRc/CMV vector. All cDNA
fragments containing mutations were sequenced before transfection.
Stable expression, purification, and characterization of
recombinant proteins.
The cDNAs corresponding to wild-type (WT) protein C and
protein C variants QGN, SEDY, and QGNSEDY, all inserted into the
eukaryotic expression vector pRc/CMV, were transfected into HEK 293 cells (CRL-1573 ATCC), high-expressing colonies selected, and
recombinant protein C purified, as previously described.33
The purity and integrity of the isolated protein C was evaluated by
10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). The GNED protein C variant used as
control has been characterized previously.8 Protein C
concentrations were quantified by measurement of absorbance at 280 nm
using an extinction coefficient of 14.5 (280 nm, 1%, 1 cm). The
purified proteins were subjected to amino acid analysis after acid
hydrolysis and Gla analysis after basic hydrolysis using methods
previously detailed.34
Activation of protein C and catalytic activity against small
substrates.
The recombinant protein C variants were activated by thrombin, and the
thrombin was removed by chromatography, essentially as previously
described.8 APC concentrations were estimated by measuring
absorbance at 280 nm. Amidolytic activities were determined using
chromogenic substrate S-2366.
Functional activity analysis
Coagulation assays.
The anticoagulant effects of APC variants were measured in 2 plasma-based assay systems, one using an APTT reaction (intrinsic pathway), the other a tissue factor (thromboplastin; extrinsic pathway)-initiated clotting reaction. An Amelung KC10
apparatus was used. In the APTT assay, 50 µL normal human pooled
plasma and 50 µL APTT LS reagent were mixed and incubated at 37°C
for 200 seconds. Coagulation was initiated by the addition of 50 µL CaCl2 (25 mM). The APC was included in the
CaCl2 reagent, and the concentrations given in the figures
refer to the concentration in the CaCl2 mixture. The
extrinsic pathway system used Simplastin Excel diluted 1:50 in Tris
(tris(hydroxymethyl)aminomethane)-buffered saline (TBS)
buffer containing 25 mM CaCl2. The Simplastin reagent contains tissue factor and negatively charged phospholipids. In the
assay, 50 µL plasma was incubated with 50 µL APC at 37°C for 200 seconds before the addition of 100 µL of the diluted Simplastin Excel
reagent that initiated the clotting reaction. Clotting times were
reported as the average and range of 2 determinations.
Factor Va degradation assay.
Plasma-purified FVa as well as FV from diluted plasma were used as
substrates for APC in the degradation assay, and the FVa activity was
measured in a prothrombinase assay. In the prothrombinase-based FVa
assay, a prothrombinase (PTase) mixture containing 0.5 µM prothrombin
and 50 µM phospholipid vesicles (10:90, wt/wt, PS/PC) was prepared in
25 mM HEPES, 150 mM NaCl, and 2 mM CaCl2, pH 7.7, containing 0.5 mg/mL ovalbumin (HNO buffer). Purified FV (0.8 nM) was
activated by thrombin (final concentration, 0.5 U/mL) at 37°C for 10 minutes. To measure the FVa activity, FXa (final concentration, 5 nM)
and the FVa samples were added to the PTase mix, and after 2 minutes
the prothrombin activation was stopped by 40-fold dilution in ice-cold
EDTA (ethylenediaminetetraacetic acid) buffer. The EDTA buffer
contained 50 mM Tris, 100 mM NaCl, 20 mM EDTA, and 1%
polyethylene glycol (PEG) 6000, pH 7.9. The amount of thrombin
formed was measured kinetically with a chromogenic substrate, S2238.
Normal plasma diluted between 1:50 and 1:1600 was used as standard in
the assay. In the degradation of FVa, FVa (final concentration, 0.8 nM)
was incubated with increasing concentrations of APC in the presence of
25 µM phospholipid vesicles (10:90, wt/wt, PS/PC) in 25 mM HEPES, 150 mM NaCl, and 5 mM CaCl2, pH 7.7, containing 5 mg/mL bovine
serum albumin (BSA; HNBSACa buffer). At defined intervals, aliquots
were drawn and diluted 1:5 in ice-cold HNBSACa buffer and kept on ice
until tested in the PTase-based FVa assay. To test if similar results
were obtained with FVa in diluted plasma, normal or APC-resistant
plasma (from an individual with homozygosity for FV Leiden) was used.
The plasmas were diluted 25-fold with HNBSACa buffer and incubated with
0.5 U/mL thrombin for 10 minutes at 37°C, which was found to yield full FV activation. APC and phospholipid vesicles were added as described in the purified system and the FVa inhibition followed as
described above. To determine the effect of protein S on FVa degradation, purified human protein S was included in the
FVa-degradation assay at a final concentration of 100 nM.
Western blotting
Protein binding to phospholipid membranes Light scattering.
Protein-membrane interaction was measured with light scattering at 90 degrees to the incident light using a Fluoromax-3 (Jobin Yvon)
spectrofluorometer.32 In brief, the intensity of the light scatter of phospholipid alone (I1) and after addition of
protein (I2) was measured. The ratio of the molecular
weight of the protein-vesicle complex (M2) to that of
vesicles alone (M1) was estimated from the following
relationship:
I2/I1 = (M2/M1)2(
Surface plasma resonance. The interaction between the protein C variants and immobilized phospholipid was also investigated using a BIAcore 2000 biosensor instrument (Biacore, Uppsala, Sweden) as described.36 The phospholipid vesicles used for these experiments were prepared by extrusion. The phospholipid vesicles were then captured on the surface of L1 sensor chip.37 Extruded liposomes with different compositions were used in the different flow cells. In cell 1, 50 µL of 0.05 mM PC vesicles (100%) was injected at a flow rate of 5 µL/min. In cell 2, 50 µL of 0.125 mM PS/PC (20%:80%) was injected at a flow rate of 2 µL/min. The buffer used was 10 mM HEPES, 150 mM NaCl, pH 7.4. The degree of coverage of the surface was measured by increase in resonance units (RUs). The slightly different conditions for PC and PS/PC vesicles were chosen because they resulted in similar levels of RUs (around 7000 RUs). The capture process permits the liposome to retain the lipid bilayer structure.38 After liposome binding, a 15 µL injection of 8 mg/mL BSA resulted in an increased signal of only 100 RUs, indicating that the dextran is no longer accessible but covered by lipid. The protein C variants in 10 mM HEPES, 150 mM NaCl, 5 mM CaCl2, pH 7.4, containing 1 mg/mL BSA were injected at different concentrations (flow rate of 30 µL/min; association phase), and the dissociation was then followed after change to buffer alone. Membranes were regenerated by injection of 5 mM EDTA (pH 8.0).
Expression and purification of recombinant protein C variants The expression levels of the different protein C variants were similar: 3 to 5 mg/L. The proteins were collected under serum-free conditions and purified with overall recoveries of 35% to 40%. The Gla content was determined after basic hydrolysis and found to be 6.3, 6.8, 7, 6.7, and 10.0 for plasma protein C, WT protein C, QGN-, SEDY-, and QGNSED-protein C, respectively. On SDS-PAGE, mutant and WT protein C migrated to similar positions consistent with a relative molecular mass (Mr) of approximately 60 000 (Figure 1). After reduction, the ,  , and  isoforms of the heavy chain as well as the light
chain are seen. In addition, all variants contained a certain
amount of the single-chain form. After activation by thrombin, the
heavy-chain isoforms shifted to slightly lower-molecular-weight positions, consistent with full activation. In addition, the
single-chain bands disappeared.
Phospholipid binding of protein C variants Two approaches were used to quantify the protein-membrane interaction, one being surface plasmon resonance, the other light scattering. In the surface plasmon resonance-based assay, phospholipid membranes of defined composition were immobilized on an L1 sensor chip. The method allowed simultaneous investigation of several phospholipid compositions. Two conditions were used, one being pure PC and the other a mixture of 20% PS and 80% PC (20:80, wt/wt). Protein C was injected, and the binding to the immobilized membrane was followed over time. The response obtained with pure PC-containing membranes was subtracted from that obtained with the PS/PC membranes. To compare the various protein C variants, they were all injected at a concentration of 0.25 µM and the binding followed over time (Figure 2A). Under these conditions, WT protein C yielded a weak binding signal in contrast to the mutant QGNSEDY, which resulted in a rapid increase in binding signal. To put the protein C variants into the perspective of membrane-binding ability of previous protein C variants prepared in our laboratory, the GNED variant was tested under the same conditions. This protein C variant was previously shown with light-scattering techniques to have around 10-fold higher affinity for PS/PC membranes than WT protein C.8 The GNED variant bound better than WT protein C but less efficiently than the QGNSEDY variant. The QGN variant yielded a pattern similar to that of WT protein C, whereas SEDY bound slightly better than WT protein C but less efficiently than GNED- and QGNSEDY-protein C.
To further characterize the binding of WT protein C and the QGNSEDY
variant to the phospholipid, increasing concentrations of protein were
injected over the phospholipid surface (Figure 2B). The 3 curves
generated by WT protein C were obtained with protein C concentrations
between 250 and 1000 nM, whereas the 3 curves obtained for QGNSEDY were
generated by protein concentrations between 62.5 and 250 nM. From the
shape of the binding curve and the amplitude of the signal, it is
obvious that QGNSEDY interacted more efficiently with the membrane than
did WT protein C. Of particular note is the observation that both the
association and dissociation are faster for QGNSEDY than WT protein C. The shape of the binding curves indicated that both the association and
dissociation reactions were complex and, because the mode of
interaction is unknown, the rate constants could not be calculated. To
circumvent this problem, another approach to determine the binding
constants for the 2 proteins was used. In this experiment, increasing
concentrations of protein were infused and the binding reactions were
allowed to proceed until steady state was reached when the association and dissociation were equal. The observed binding responses were plotted against the protein concentrations, yielding binding curves that allowed calculation of equilibrium binding constants (Figure 2C).
The data were evaluated with the BIAcore evaluation program using
equation
KA = Req/C(Rmax The protein-membrane binding was also measured with the light-scattering technique, which gives information about the equilibrium binding constants but not the rates of binding. The experimental data are shown in Figure 2D, and the derived Kd's for WT protein C, SEDY, QGN, and QGNSEDY were 7.3 µM, 4.6 µM, 6.8 µM, and 2.2 µM, respectively. The QGNSEDY variant demonstrated higher affinity for the membrane than did WT protein C. The QGN variant behaved like WT protein C, whereas the SEDY variant yielded results intermediate of those obtained with WT protein C and the QGNSEDY variant. The GNED variant was also tested and gave similar binding as QGNSEDY. However, the binding of GNED was not fully reversed by the addition of EDTA, and a Kd was therefore not calculated. Anticoagulant activities of activated protein C variants in plasma To investigate the anticoagulant potential of the various protein C variants, 2 clotting systems were tested using normal human plasma. One of the systems was based on activation of the intrinsic system (APTT), the other being dependent on initiation of coagulation by tissue factor (PT assay; Figure 3). In the APTT-based system, increasing concentrations of WT APC yielded prolongation of clotting time to approximately 200 seconds at the highest APC concentration tested. The response to the GNED variant was similar to that of WT APC, whereas both QGN and SEDY were more potent as anticoagulants than WT APC, resulting in clotting times around 400 seconds at the highest concentrations tested. The QGNSEDY-APC variant was considerably more potent than any of the other variants, with clotting times reaching more than 1000 seconds at the highest concentration tested.
In the PT-based assay, the results were somewhat different; the GNED-APC mutant was more active than both QGN-APC and SEDY-APC (Figure 3B). These 2 APC variants were only slightly more active than WT APC. The QGNSEDY-APC variant was highly efficient as anticoagulant and yielded a clotting time of more than 1000 seconds at the highest concentration tested. Even the lowest concentration of this APC variant was more efficient in prolonging the clotting time than the highest concentration of WT APC, suggesting the QGNSEDY variant in this system to be at least 20-fold more active than WT APC. Addition of WT APC to plasma from an individual with homozygosity for
FV Leiden did not prolong the clotting time, yielding an APC ratio of
around 1. In contrast, the QGNSEDY-APC variant had a distinct
anticoagulant effect in this plasma, resulting in an APC ratio of more
than 2 at the 10 nM concentration of APC (Figure
4).
Degradation of FVa by activated protein C variants In an FVa-degradation system, either using purified FV or diluted plasma as source of FVa, increasing concentrations of WT APC resulted in partial loss of FVa activity (Figure 5A). Results obtained with purified FVa and diluted plasma were similar, suggesting the latter system to adequately reflect FVa degradation. Approximately 25% FVa activity remained at the highest concentration of APC used, suggesting that the Arg506 cleavage had occurred, whereas the Arg306 site was not completely cleaved. The QGN- and SEDY-APC variants were somewhat more active than WT APC but only at the highest concentration used. In contrast, the QGNSEDY-APC variant was highly efficient in inhibiting FVa even at low concentrations. This suggests the Arg306 site to be cleaved, which resulted in complete loss of FVa activity. The GNED-APC variant demonstrated intermediate activity between WT APC and the QGNSEDY-APC variant, indicating that the Arg306 site had been cleaved. The FVa degradation was also followed over time (Figure 5B). The initial rapid loss of activity obtained in the presence of WT APC is the result of cleavage at Arg506. The FVa activity reached a plateau with 40% to 50% remaining activity after 10 to 15 minutes. The QGN- and SEDY-APC variants were only slightly more active than WT APC. In contrast, the QGNSEDY-APC was highly efficient and only around 20% FV activity remained after the first 5 minutes of incubation. The results suggest that both the Arg506 and the Arg306 sites were cleaved more rapidly by the QGNSEDY-APC variant than by WT APC. These conclusions were supported by the results of Western blotting of samples drawn from an FV degradation assay (Figure 6). In the presence of WT APC, only the Arg506 site is cleaved, which results in the generation of a 75 kDa band (corresponds to residues 1-506). In contrast, QGNSEDY-APC generates a strong 30 kDa band, which is the result of cleavages at both Arg506 and Arg306.
The conclusions drawn from the degradation of normal FVa were supported by results obtained using FVa Leiden (Figure 5C-D). In this case, FVa degradation is dependent mainly on the cleavage at the Arg306 site, because Gln replaces the Arg506. Increasing concentrations of WT APC resulted in a gradually increased loss of FVa activity, the highest APC concentration (3 nM) yielding approximately 40% remaining activity. The QGNSEDY-APC variant was considerably more efficient, and approximately 10-fold lower concentrations of QGNSEDY-APC as compared to WT APC were needed to obtain similar loss of FVa activity. A study of the time course of the FVa degradation demonstrated the slow loss of FVa activity obtained when WT APC was used. In contrast, the QGNSEDY-APC yielded a rapid inhibition of FVa activity, which was due to enhanced rate of cleavage of the Arg306 site. Protein S was found to stimulate the rate of degradation of normal FVa
as well as of FVa Leiden (Figure 7). In
FVa degradation, the Arg306 cleavage is stimulated by the presence of
protein S, whereas the Arg506 cleavage site is unaffected. As a
consequence, the difference observed between the degradation curves
obtained in the presence and absence of protein S is due to increased
rate of cleavage at the Arg306 site. The QGNSEDY-APC variant was also stimulated by the presence of protein S. Similar effects were observed
in the degradation of FVa Leiden, which is consistent with the protein
S effect being related to stimulation of the cleavage at Arg306. It is
noteworthy that in the degradation of both normal FVa and FVa Leiden,
the QGNSEDY variant in the absence of protein S was more potent than WT
APC in the presence of protein S.
The Gla domains of different vitamin K-dependent proteins are very similar, sharing a high degree of sequence identity with certain positions being completely conserved.6 In particular the Gla residues tend to be conserved, which is consistent with their role in the calcium-dependent folding of the Gla domain. In addition, the Gla domains contain 3 hydrophobic residues at positions 4, 5, and 8 (corresponding to positions 5, 6, and 9 in prothrombin and FIX) that are hypothesized to intercalate into the hydrophobic part of the phospholipid membrane.39-41 Despite the extensive similarities between the different Gla domains, their affinities for negatively charged phospholipid membranes vary considerably over a 1000-fold range.6 There are not only differences between various proteins but also between the same protein of 2 distinct species. Thus, human protein C binds to phospholipid membranes with 10-fold higher affinity than its bovine counterpart, which is due to an amino acid residue difference at position 10. A Pro to His replacement at position 10 in recombinant bovine protein C was found to result in a 10-fold increase in membrane-binding affinity, proving that improved membrane-binding ability may be achieved by mutagenesis of certain residues in the Gla domain.7 Further support for this concept was derived from mutagenesis studies of factor VII, which converted factor VII into a high-affinity membrane-binding protein.9 Human protein C has also been the subject of similar mutagenesis studies, which resulted in several protein C variants having enhanced membrane-binding ability and, in parallel, increased anticoagulant potential.7,8 In the previously investigated human protein C variants, Gln and Asn occupying positions 32 and 33 in WT protein C were replaced with Glu and Asp, respectively, Glu at position 32 being expected to be carboxylated to Gla.8 These mutations did not in themselves affect the membrane-binding ability of the recombinant protein C variants. However, when combined with single or double mutagenesis of amino acids His10 (to Glu or Gln), Ser11 (to Gly), and Ser12 (Asn), a number of protein C variants with enhanced phospholipid- and calcium-binding ability were obtained, and several of them demonstrated increased anticoagulant activity as well.8 The present investigation is an extension of our previous work and aimed both at identification of even more potent protein C variants and the creation of protein C reagents useful for in vitro and in vivo experimentation on phospholipid binding. In addition, we wanted to test the hypothesis that multiple positions at very different positions in the Gla domain affect the membrane-binding characteristics and the anticoagulant potential of the protein. The selection of positions for mutagenesis in this investigation was the result of a combination of sequence comparison of different Gla domains and 3-dimensional structural analysis. A recently developed model of full-length protein C was instrumental for the structural analysis.42 The 3 recombinant protein C variants, QGN, SEDY, and QGNSEDY, were chosen for several reasons. The QGN variant was only mutated at positions 10 to 12, with the purpose to investigate whether such a modification would be sufficient to increase phospholipid binding ability per se. The SEDY variant, on the other hand, was a modification of a previously investigated protein C variant denoted ED (E32D33). In this variant, S23 was introduced because several of the high-affinity phospholipid-binding Gla domains have Ser at position 23, whereas in human protein C this position is occupied with Asp. The Y44 mutation was introduced because the Gla domain of human protein C is unique in having His at position 44. Even all the protein C's from other species have Tyr at position 44. The fully mutated variant QGNSEDY was a combination of the QGN and SEDY variants, which allowed questions to be asked concerning whether multiple regions had to be modified in order to create a protein with high-affinity binding to negatively charged phospholipid. The phospholipid binding of the purified protein C variants was investigated with light scattering as well as with surface plasmon resonance. Membrane binding of vitamin K-dependent coagulation factors have previously been determined by ellipsometry,43,44 light scattering,6,45,46 and fluorescence polarization.47 Recently, the utility of BIAcore technique for evaluation of membrane-binding ability of vitamin K-dependent proteins has been demonstrated.36,38 In the BIAcore, the Kd for the QGNSEDY variant was found to be around 0.5 µM, suggesting the equilibrium binding affinity to be considerably higher than that of WT protein C, which yielded a Kd of 3.5 µM. The corresponding values obtained in the light-scattering experiment were 2.2 µM and 7.3 µM, respectively. The Kd values now obtained for WT protein C binding to phospholipid are in good agreement with results on record derived from light-scattering experiments.8 The BIAcore not only yielded equilibrium binding constants but demonstrated that both the rates of association and dissociation were much higher for the QGNSEDY variant than for WT protein C. The faster kinetics of membrane interaction of QGNSEDY may be of particular importance for its enhanced anticoagulant efficiency. It was noteworthy that the QGNSEDY-APC variant was a potent anticoagulant even in a normal APTT reaction. Previously characterized protein C variants only demonstrated enhanced anticoagulant activity in systems with diluted phospholipid reagents (ie, at low concentrations of the membrane).7,8 Consistent with these observations, we now found the GNED-APC variant not to enhance anticoagulant activity in the undiluted APTT system. In contrast, the diluted tissue factor (PT) system contained low phospholipid levels and the GNED-APC was more potent as anticoagulant than WT APC, which is also consistent with results on record. The APC variants were also evaluated in a system investigating the degradation of normal FVa and FVa Leiden (Arg506Gln). In the absence of protein S, the rate of Arg506 cleavage in normal FVa is 10-fold higher than that of Arg306 but only results in partial FVa inactivation. The slower cleavage at Arg306 results in complete inhibition of FVa activity. This cleavage is stimulated by the presence of protein S, which is believed to affect the activity in APC by dual mechanisms.19 First, protein S and APC form a complex on the phospholipid membrane, with protein S enhancing the membrane-binding ability of APC approximately 10-fold. Second, the protein S-APC interaction affects the location of the active site of APC, reducing the distance of the active site from the membrane by approximately 1.0 nm.14,15 From the degradation curves of normal FVa and FVa Leiden obtained in the absence of protein S, it is evident that the QGNSEDY-APC is highly efficient in cleaving FVa and that both the Arg506 and the Arg306 sites are cleaved at an enhanced rate by this APC variant. The main conclusion from the FVa-degradation system is that the enhanced membrane-binding ability of QGNSEDY-APC results in increased levels of active APC on the membrane, which results in enhanced efficiency of FVa degradation. The enhanced membrane affinity of QGNSEDY-APC was found to stimulate cleavage of Arg306 even in the absence of protein S, which demonstrates the importance of the membrane binding of APC for this cleavage. APC has been demonstrated to be highly efficient in the treatment of sepsis, which is related to its anticoagulant activity as well as to a poorly defined anti-inflammatory function of APC.25,26 It is tempting to speculate that APC variants with enhanced anticoagulant activity resulting from improved membrane-binding ability may prove more efficient than WT APC in the treatment of sepsis. The low-affinity binding of APC to negatively charged phospholipid membranes may under normal healthy conditions be adequate, because protein S serves as a specific cofactor to increase the membrane binding of APC at certain locations. The situation may be different in pathologic conditions such as sepsis where higher membrane-binding ability of APC could potentially be beneficial, in particular because protein S and FV may be consumed in these conditions. The creation of the now-described QGNSEDY-APC variant will allow in vivo elucidation of the biologic consequences of enhanced membrane-binding ability of protein C and may open a path for development of APC variants with improved therapeutic potential in sepsis as well as other thromboembolic disorders.
The authors thank Dr Anna Blom and Miss Eva Norstrom for valuable advice and Mrs Astra Andersson and Mrs Ing-Marie Persson for expert technical assistance.
Submitted June 10, 2002; accepted November 1, 2002.
Prepublished online as Blood First Edition Paper, November 21, 2002; DOI 10.1182/blood-2002-06-1691.
Supported by a senior investigator award from the Swedish Foundation for Strategic Research, the Swedish Medical Research Council (grant no. 07143), the Albert Påhlsson Trust, and research funds from the University Hospital, Malmö.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Björn Dahlbäck, Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, The Wallenberg Laboratory, University Hospital, Malmö, SE-205 02 Malmö, Sweden; e-mail: bjorn.dahlback{at}klkemi.mas.lu.se.
1. Zwaal RF, Comfurius P, Bevers EM. Lipid-protein interactions in blood coagulation. Biochim Biophys Acta. 1998;1376:433-453[Medline] [Order article via Infotrieve]. 2. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem. 1988;57:915-956[CrossRef][Medline] [Order article via Infotrieve]. 3. Furie B, Furie BC. The molecular basis of blood coagulation. Cell. 1988;53:505-518[CrossRef][Medline] [Order article via Infotrieve].
4.
Nelsestuen GL.
Enhancement of vitamin-K-dependent protein function by modification of the 5. Vermeer C. Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase. Biochem J. 1990;266:625-636[Medline] [Order article via Infotrieve]. 6. McDonald JF, Shah AM, Schwalbe RA, et al. Comparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. Biochemistry. 1997;36:5120-5127[CrossRef][Medline] [Order article via Infotrieve]. 7. Shen L, Shah AM, Dahlbäck B, Nelsestuen GL. Enhancing the activity of protein C by mutagenesis to improve the membrane-binding site: studies related to proline-10. Biochemistry. 1997;36:16025-16031[CrossRef][Medline] [Order article via Infotrieve].
8.
Shen L, Shah AM, Dahlbäck B, Nelsestuen GL.
Enhancement of human protein C function by site-directed mutagenesis of the
9.
Shah AM, Kisiel W, Foster DC, Nelsestuen GL.
Manipulation of the membrane binding site of vitamin K-dependent proteins: enhanced biological function of human factor VII.
Proc Natl Acad Sci U S A.
1998;95:4229-4234 10. Nicolaes GA, Villoutreix BO, Dahlbäck B. Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation. Biochemistry. 1999;38:13584-13591[CrossRef][Medline] [Order article via Infotrieve]. 11. Dahlbäck B. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management. Semin Hematol. 1997;34:217-234[Medline] [Order article via Infotrieve].
12.
Esmon CT, Gu JM, Xu J, et al.
Regulation and functions of the protein C anticoagulant pathway.
Haematologica.
1999;84:363-368
13.
Walker FJ.
Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation.
J Biol Chem.
1981;256:11128-11131
14.
Yegneswaran S, Wood GM, Esmon CT, Johnson AE.
Protein S alters the active site location of activated protein C above the membrane surface. A fluorescence resonance energy transfer study of topography.
J Biol Chem.
1997;272:25013-25021
15.
Yegneswaran S, Smirnov MD, Safa O, et al.
Relocating the active site of activated protein C eliminates the need for its protein S cofactor. A fluorescence resonance energy transfer study.
J Biol Chem.
1999;274:5462-5468
16.
Kalafatis M, Rand MD, Mann KG.
The mechanism of inactivation of human factor V and human factor Va by activated protein C.
J Biol Chem.
1994;269:31869-31880
17.
Nicolaes GA, Tans G, Thomassen MC, et al.
Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C.
J Biol Chem.
1995;270:21158-21166
18.
Kalafatis M, Bertina RM, Rand MD, Mann KG.
Characterization of the molecular defect in factor VR506Q.
J Biol Chem.
1995;270:4053-4057
19.
Rosing J, Hoekema L, Nicolaes GA, et al.
Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C.
J Biol Chem.
1995;270:27852-27858
20.
Shen L, Dahlbäck B.
Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa.
J Biol Chem.
1994;269:18735-18738 21. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67[CrossRef][Medline] [Order article via Infotrieve].
22.
Dahlbäck B, Hildebrand B.
Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.
Proc Natl Acad Sci U S A.
1994;91:1396-1400 23. Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res. 1995;77:1-43[CrossRef][Medline] [Order article via Infotrieve]. 24. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost. 2001;86:51-56[Medline] [Order article via Infotrieve]. 25. Rintala E, Seppala OP, Kotilainen P, Pettila V, Rasi V. Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med. 1998;26:965-968[CrossRef][Medline] [Order article via Infotrieve].
26.
Bernard GR, Vincent JL, Laterre PF, et al.
Efficacy and safety of recombinant human activated protein C for severe sepsis.
N Engl J Med.
2001;344:699-709 27. Dahlbäck B. Purification of human vitamin K-dependent protein S and its limited proteolysis by thrombin. Biochem J. 1983;209:837-846[Medline] [Order article via Infotrieve].
28.
Suzuki K, Stenflo J, Dahlbäck B, Teodorsson B.
Inactivation of human coagulation factor V by activated protein C.
J Biol Chem.
1983;258:1914-1920 29. Laurell M, Ikeda K, Lindgren S, Stenflo J. Characterization of monoclonal antibodies against human protein C specific for the calcium ion-induced conformation or for the activation peptide region. FEBS Lett. 1985;191:75-81[CrossRef][Medline] [Order article via Infotrieve]. 30. Dahlbäck B. Human coagluation factor V purification and thrombin-catalyzed activation. J Clin Invest. 1980;66:583-591[Medline] [Order article via Infotrieve].
31.
Rosing J, Bakker HM, Thomassen MC, Hemker HC, Tans G.
Characterization of two forms of human factor Va with different cofactor activities.
J Biol Chem.
1993;268:21130-21136 32. Nelsestuen GL, Lim TK. Equilibria involved in prothrombin- and blood clotting factor X-membrane binding. Biochemistry. 1977;16:4164-4171[CrossRef][Medline] [Order article via Infotrieve]. 33. Friedrich U, Potzsch B, Preissner KT, Muller-Berghaus G, Ehrlich H. Calcium-dependent activation of protein C by thrombin/thrombomudulin: role of negatively charged amino acids within the activation peptide of protein C. Thromb Haemost. 1994;72:567-572[Medline] [Order article via Infotrieve].
34.
Dahlbäck B, Lundwall A, Stenflo J.
Localization of thrombin cleavage sites in the amino-terminal region of bovine protein S.
J Biol Chem.
1986;261:5111-5115
35.
Norstrom E, Thorelli E, Dahlbäck B.
Functional characterization of recombinant FV Hong Kong and FV Cambridge.
Blood.
2002;100:524-530 36. Erb EM, Stenflo J, Drakenberg T. Interaction of bovine coagulation factor X and its glutamic-acid-containing fragments with phospholipid membranes. A surface plasmon resonance study. Eur J Biochem. 2002;269:3041-3046[Medline] [Order article via Infotrieve]. 37. Cooper MA, Hansson A, Lofas S, Williams DH. A vesicle capture sensor chip for kinetic analysis of interactions with membrane-bound receptors. Anal Biochem. 2000;277:196-205[CrossRef][Medline] [Order article via Infotrieve]. 38. Erb EM, Chen X, Allen S, et al. Characterization of the surfaces generated by liposome binding to the modified dextran matrix of a surface plasmon resonance sensor chip. Anal Biochem. 2000;280:29-35[CrossRef][Medline] [Order article via Infotrieve]. 39. Christiansen WT, Jalbert LR, Robertson RM, et al. Hydrophobic amino acid residues of human anticoagulation protein C that contribute to its functional binding to phospholipid vesicles. Biochemistry. 1995;34:10376-10382[CrossRef][Medline] [Order article via Infotrieve]. 40. Seshadri TP, Skrzypczak-Jankun E, Yin M, Tulinsky A. Differences in the metal ion structure between Sr- and Ca-prothrombin fragment 1. Biochemistry. 1994;33:1087-1092[CrossRef][Medline] [Order article via Infotrieve]. 41. Sunnerhagen M, Forsen S, Hoffren AM, et al. Structure of the Ca(2+)-free Gla domain sheds light on membrane binding of blood coagulation proteins. Nat Struct Biol. 1995;2:504-509[CrossRef][Medline] [Order article via Infotrieve]. 42. Villoutreix BO, Covell DG, Blom AM, et al. Screening the molecular surface of human anticoagulant protein C: a search for interaction sites. J Comput Aided Mol Des. 2001;15:13-27[CrossRef][Medline] [Order article via Infotrieve].
43.
Giesen PL, Willems GM, Hemker HC, Hermens WT.
Membrane-mediated assembly of the prothrombinase complex.
J Biol Chem.
1991;266:18720-18725 44. Willems GM, Janssen MP, Salemink I, Wun TC, Lindhout T. Transient high affinity binding of tissue factor pathway inhibitor-factor Xa complexes to negatively charged phospholipid membranes. Biochemistry. 1998;37:3321-3328[CrossRef][Medline] [Order article via Infotrieve]. 45. Cutsforth GA, Whitaker RN, Hermans J, Lentz BR. A new model to describe extrinsic protein binding to phospholipid membranes of varying composition: application to human coagulation proteins. Biochemistry. 1989;28:7453-7461[CrossRef][Medline] [Order article via Infotrieve]. 46. Nelsestuen GL, Kisiel W, Di Scipio RG. Interaction of vitamin K dependent proteins with membranes. Biochemistry. 1978;17:2134-2138[CrossRef][Medline] [Order article via Infotrieve].
47.
Nesheim ME, Kettner C, Shaw E, Mann KG.
Cofactor dependence of factor Xa incorporation into the prothrombinase complex.
J Biol Chem.
1981;256:6537-6540
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  R. J. S. Preston, E. Ajzner, C. Razzari, S. Karageorgi, S. Dua, B. Dahlback, and D. A. Lane Multifunctional Specificity of the Protein C/Activated Protein C Gla Domain J. Biol. Chem., September 29, 2006; 281(39): 28850 - 28857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Feistritzer, B. A. Mosheimer, D. H. Sturn, M. Riewald, J. R. Patsch, and C. J. Wiedermann Endothelial Protein C Receptor-Dependent Inhibition of Migration of Human Lymphocytes by Protein C Involves Epidermal Growth Factor Receptor J. Immunol., January 15, 2006; 176(2): 1019 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schuettrumpf, R. W. Herzog, A. Schlachterman, A. Kaufhold, D. W. Stafford, and V. R. Arruda Factor IX variants improve gene therapy efficacy for hemophilia B Blood, March 15, 2005; 105(6): 2316 - 2323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-H. Sun, S. Tran, E. A. Norstrom, and B. Dahlback Enhanced Rate of Cleavage at Arg-306 and Arg-506 in Coagulation Factor Va by Gla Domain-mutated Human-activated Protein C J. Biol. Chem., November 12, 2004; 279(46): 47528 - 47535. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
); SEDY, (
); QGN, (
); WT protein C,
(
). The means of 2 to 3 different experiments are shown with error
bars representing ± SD.
Req).
C is the concentration of protein, Rmax is the total
surface binding capacity in RUs, and Req is the
steady-state binding level in RUs. The Rmax and Kd values were allowed to vary to obtain the
best fit to the data points. In the case of QGNSEDY, the calculation
yielded an Rmax of 475, which fits well with the results
presented in Figure 
); QGN-APC, (
); WT APC, with human protein S (